Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026
Same author

The Relevance of Curative-Intent Metastasectomy in Colorectal Cancer Patients: Real-World Insights From a Certified Comprehensive Cancer Center in Germany.

International journal of cancer·2026
Same author

Amivantamab Monotherapy in Chemorefractory <i>RAS</i>/<i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial.

Nature communications·2026
Same author

Gastric and rectal administration of encorafenib with targeted chemotherapy against BRAF V600E-mutant rectal cancer with bowel obstruction.

The oncologist·2026
Same author

A Mobile Exhibition to Advance Cancer Prevention Awareness: A Cross-Sectional Evaluation Using the RE-AIM Framework.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026

Related Experiment Video

Updated: Jul 10, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

[Neoadjuvant and adjuvant therapies for solid tumours].

Volker Heinemann1, Nicolas Moosmann

  • 1Medizinische Klinik und Poliklinik III, Klinikum Grosshadern LMU München. Volker.Heinemann@med.uni-muenchen.de

MMW Fortschritte Der Medizin
|October 20, 2007
PubMed
Summary

Adjuvant and neoadjuvant therapies are standard cancer treatments that improve cure rates and reduce relapse risk. Ongoing studies investigate targeting epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) to enhance treatment effectiveness.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Experiment Videos

Last Updated: Jul 10, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Area of Science:

  • Oncology
  • Cancer Therapeutics
  • Clinical Research

Background:

  • Adjuvant and neoadjuvant therapies are integral to modern cancer treatment protocols.
  • These treatments, including chemotherapy, radiotherapy, hormone therapy, and immunotherapy, are administered before, during, or after surgery.
  • Their application aims to reduce cancer recurrence and improve patient survival rates.

Purpose of the Study:

  • To summarize the role and application of adjuvant and neoadjuvant therapies in cancer management.
  • To highlight the potential benefits, such as organ preservation after neoadjuvant treatment.
  • To introduce ongoing research into novel therapeutic targets, specifically growth factors.

Main Methods:

  • Review of current clinical practices for adjuvant and neoadjuvant cancer therapies.
  • Analysis of treatment strategies based on relapse risk and benefit-risk assessment.
  • Identification of emerging research areas focusing on growth factor modulation.

Main Results:

  • Adjuvant and neoadjuvant therapies are established methods for lowering relapse risk and increasing cure probability.
  • Neoadjuvant therapy can lead to organ preservation, potentially avoiding extensive surgery.
  • Clinical studies are actively exploring the modulation of epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF).

Conclusions:

  • Adjuvant and neoadjuvant therapies significantly contribute to improved cancer outcomes.
  • The strategic application of these therapies requires careful consideration of individual patient risk.
  • Targeting growth factors like EGF and VEGF represents a promising frontier in cancer treatment research.